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controlled trials (RCTs), NOACs reduced the risk 
of stroke or SE by 19% compared with warfarin 
(relative risk [RR], 0.81; 95% CI, 0.73–0.91), large­
ly due to a markedly lower rate of hemorrhagic 
strokes (RR 0.49, 95% CI, 0.38–0.64) and intracra­
nial bleeding (ICB) (RR, 0.48; 95% CI, 0.39–0.59).9 
However, the use of NOACs (in particular, full­
­dose dabigatran and rivaroxaban) was signifi­
cantly associated with an increased risk of gas­
trointestinal (GI) bleeding (RR, 1.25; 95% CI, 
1.01–1.55).7 Of note, the differences between 
baseline stroke and bleeding risks among differ­
ent NOAC trials could have affected the report­
ed bleeding rates (FIguRE 1). Residual incidence 
of stroke or SE despite NOAC use among pa­
tients with AF is estimated at 1.5% to 2.5% per 
year and that of major bleeding at 2% to 4% per 
year.9 As compared with warfarin, NOACs slight­
ly reduced all ­cause mortality (RR, 0.89; 95% CI, 
0.85–0.94), vascular mortality (RR, 0.88; 95% 
CI, 0.82–0.94), and bleeding ­related mortality 
(RR, 0.54; 95% CI, 0.44–0.67).10 Importantly, in 
the phase 3 AF trials, NOACs were more effective 
than warfarin in the prevention of stroke or SE 
among patients with AF aged 75 years or older.11
Introduction Atrial fibrillation (AF) is the most 
common sustained cardiac arrhythmia in clini­
cal practice, and it is associated with an increased 
risk of ischemic stroke and systemic thromboem­
bolism (SE) from less than 1% to about 20% per 
year.1 Of all ischemic strokes, 20% to 30% are as­
sociated with AF and high morbidity and mortal­
ity. Oral anticoagulation therapy reduces the risk 
of stroke and SE by more than 60% in patients 
with AF,2,3 yet clinicians and patients need to con­
sider these benefits as compared with the risk of 
major bleeding.4
Non–vitamin K antagonist oral anticoagulants 
(NOACs, or direct oral anticoagulants [DOACs] 
as recommended by the International Society on 
Thrombosis and Hemostasis [ISTH], including dab­
igatran, rivaroxaban, apixaban, and edoxaban), 
have been shown in landmark phase 3 random­
ized trials to be at least noninferior to warfarin 
for the prevention of stroke and SE and are pre­
ferred over warfarin in patients with nonvalvular 
AF.5,6 When compared with vitamin K antagonist 
(VKA), the efficacy of NOACs is similar or high­
er, but they are safer and more convenient.7,8 In 
a meta ­analysis of pivotal phase 3 AF randomized 
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AbsTRACT
Major bleeding (especially intracranial hemorrhage) is the most feared adverse event observed in patients 
with atrial fibrillation (AF) receiving oral anticoagulation. Clinical risk factor–based scores have modest 
ability to predict major or clinically relevant bleeds, and blood biomarkers are increasingly implemented 
to improve bleeding prognostication in patients with AF on life ‑long anticoagulation. To improve the safety 
of anticoagulation in the era of non–vitamin K antagonist oral anticoagulants (NOACs, or direct oral 
anticoagulants [DOACs], including dabigatran, rivaroxaban, apixaban, and edoxaban), specific demo‑
graphic, clinical, and laboratory variables should be considered. The current review summarizes practi‑
cal challenges in the management of oral anticoagulation with emphasis on the risk assessment tools, 
elderly or underweight patients, cancer patients, impact of chronic kidney disease, liver cirrhosis, and 
thrombocytopenia in the context of bleeding risk in patients with AF.
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the GI tract, thus facilitating bleeding from vul­
nerable lesions.19
scoring systems to predict bleeding in atrial fibrillation 
The most commonly used definition of major 
bleeding in nonsurgical patients according to 
the ISTH includes:
1 fatal bleeding, and / or
2 symptomatic bleeding in a critical area or or­
gan, for example, intracranial, intraspinal, intra­
ocular, retroperitoneal, intraarticular or pericar­
dial, or intramuscular bleeding with compartment 
syndrome, and / or
3 bleeding accompanied by a decrease in the he­
moglobin level of 2 g/dl or higher or leading to 
transfusion of 2 or more units of whole blood or 
packed red blood cells.20
The annual rates of major bleeding range from 
1.3% to 7.2% in patients with AF on VKA treat­
ment.21 Various bleeding risk scores (TAbLE 1) have 
been developed to assess the risk of bleeding in 
patients with AF taking oral anticoagulant ther­
apy.22,23 All these scores have a relatively mod­
est ability to predict bleeding events (as reflect­
ed by the C statistic values in the range from 0.50 
to 0.65), and numerous studies comparing 2 or 
more bleeding risk scores yielded conflicting re­
sults.24-33 In a systemic review commissioned by 
the Patient ­Centered Outcomes Research Insti­
tute34 of 38 studies on bleeding risk prediction, 
the HAS ­BLED (hypertension, abnormal renal 
and / or liver function, history of stroke or throm­
boembolism, history of bleeding or bleeding dia­
thesis [eg, severe anemia], age >65 years, use of 
aspirin or nonsteroidal anti ­inflammatory drugs, 
and alcohol abuse) score had the best evidence for 
A  systematic review by Chai ­Adisaksopha 
et al,12 which included 12 RCTs involving 102 607 
patients at the average age of 70 to 73 years in 
the 5 AF trials and 54 to 57 years in the 7 venous 
thromboembolism (VTE) trials, clearly demon­
strated that the incidence of ICB, the most feared 
hemorrhagic adverse event, in patients receiving 
NOACs is reduced by over 50% compared with 
warfarin. Of all major bleeding episodes among 
VKA users, 8.7% were ICB with a 46% to 55% 
mortality rate.13,14 Patients with AF or VTE on 
NOACs had a lower risk of overall major bleed­
ing (RR, 0.72; number needed to treat [NNT], 
156), fatal bleeding (RR, 0.53; NNT, 454), clini­
cally relevant nonmajor bleeding (RR, 0.78; NNT, 
99), and all bleeding (RR, 0.76; NNT, 18), with­
out increased risk of GI bleeding (RR, 0.94; 95% 
CI, 0.88–1.34).12 Several systematic reviews com­
paring NOACs with standard care demonstrat­
ed a 20% higher GI bleeding rate in patients on 
a NOAC.15,16 A significant increase in the risk of 
GI bleeding was observed in the RCTs evaluat­
ing dabigatran and rivaroxaban in patients with 
AF.17,18 In the RE ­LY (Randomized Evaluation of 
Long ­Term Anticoagulation Therapy) trial, dabig­
atran 150 mg bid (but not dabigatran 110 mg bid) 
was associated with an increased risk of major GI 
bleeding compared with warfarin (RR, 1.50; 95% 
CI, 1.19–1.89),17 whereas in the ROCKET ­AF (Ri­
varoxaban Once ­daily Oral Direct Factor Xa Inhi­
bition Compared with Vitamin K Antagonism for 
Prevention of Stroke and Embolism Trial in Atri­
al Fibrillation), rivaroxaban 20 mg once daily in­
creased this annual risk by 1% (3.2% vs 2.2%).18 
Of note, NOAC ­associated GI bleeding is proba­
bly related to the presence of the active drug in 
FIguRE 1 Differences in thromboembolic and bleeding risk in seminal randomized controlled trials on non–vitamin K 
antagonist oral anticoagulants in atrial fibrillation 
Abbreviations: CHADS2, congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke/transient 
ischemic attack history; HAS ‑BLED, hypertension, abnormal liver function, history of stroke or thromboembolism, history 
of bleeding, age >65 years, use of nonsteroidal anti ‑inflammatory drugs, and alcohol abuse; RE ‑LY, Randomized 
Evaluation of Long ‑Term Anticoagulation Therapy; ROCKET‑AF, Rivaroxaban Once ‑daily Oral Direct Factor Xa Inhibition 
Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation; ARISTOTLE, 
Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation
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bleeding risk factors should be acknowledged, and 
such high ­risk patients should be scheduled for 
an earlier and more frequent clinical follow ­up af­
ter oral anticoagulant therapy has been initiated. 
Indeed, a formal bleeding risk assessment using 
the HAS ­BLED score has been shown to be supe­
rior to the less well ­structured approach of ad­
dressing modifiable bleeding risk factors only.37-39
Potential new biomarkers in bleeding prediction 
Most risk prediction models for bleeding in pa­
tients with AF, including HAS ­BLED, ATRIA (An­
ticoagulation and Risk Factors in Atrial Fibrilla­
tion), and ORBIT ­AF (Outcomes Registry for Bet­
ter Informed Treatment of Atrial Fibrillation) 
score, do not incorporate biomarkers, although 
predicting bleeding risk (moderate strength of ev­
idence), consistent with other systematic reviews 
and meta ­analyses comparing bleeding risk pre­
diction scores.35,36
The latest AF guidelines issued by the Euro­
pean Society of Cardiology in 2016 were focused 
on modifiable risk factors and their elimina­
tion, if possible, including the use of antiplate­
let agents, alcohol abuse, unstable anticoagulation 
with a VKA, and uncontrolled hypertension (to 
reduce the risk of ICB).7 However, nonmodifiable 
bleeding risk factors such as prior major bleed­
ing or stroke, cancer, or advanced age should not 
be ignored. Whereas modifiable bleeding risk fac­
tors should be identified and managed, the impor­
tant interaction between these and nonmodifiable 
TAbLE 1 The most common clinical bleeding scores used in patients with atrial fibrillation
Scale Risk factors Scoring point Bleeding risk stratification
HAS ‑BLED Hypertension (SBP >160 mm Hg) 1 Low risk, 0–2
High risk, 3–9Abnormal renal and / or liver function 1 point each
Stroke 1
Bleeding history 1
Labile INR 1
Elderly (>65 y) 1
Drugs (antiplatelets / NSAIDS) / concomitant / ≥8 units alcohol per week) 1 point each
HEMORR2HAGES Hepatic or renal disease 1 Low risk, 0–1
Intermediate risk, 2–3
High risk, 4–12
Ethanol abuse 1
Malignancy 1
Older (>75 y) 1
Reduced platelet count 1
Re ‑bleeding risk 2
Hypertension (uncontrolled) 1
Anemia 1
Genetic CYP2C9 polymorphisms 1
Excessive fall risk 1
Stroke / TIA history 1
ATRIA Anemia 3 Low risk, 0–3
Intermediate risk, 4
High risk, 5–10
Severe CKD 3
Age ≥75 y 2
Previous bleeding 1
Hypertension 1
ORBIT ‑AF Age (≥75 y) 1 Low risk, 0–2
Medium, risk 3
High risk ≥4
Reduced hemoglobin (<13 g/dl in men and <12 g/dl in women) 2
Hematocrit (<40% in men and <36% in women) or history of anemia 2
Bleeding history 2
Insufficient kidney function (eGFR <60 ml/min/1.73 m2) 1
Treatment with an antiplatelet agent 1
ABC ‑bleeding score Age Digitally 
calculated
Low risk <1% per year
Moderate risk, 1%–2% per year
High risk >2% per year
Biomarkers (growth differentiation factor ‑15, high ‑sensitivity cardiac 
troponin T, hemoglobin / hematocrit)
History of previous bleeding
Abbreviations: ATRIA, Anticoagulation and Risk Factors in Atrial Fibrillation; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; 
HEMORR2HAGES, Hepatic or Renal Disease, Ethanol Abuse, Malignancy, Older Age, Reduced Platelet Count or Function, Re ‑Bleeding, Hypertension, 
Anemia, Genetic Factors, Excessive Fall Risk and Stroke; INR, international normalized ratio; NSAID, non ‑steroidal anti ‑inflammatory drug; ORBIT ‑AF, 
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation; SBP, systolic blood pressure; TIA, transient ischemic attack; others, see FIguRE 1
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established whether assessing abnormalities in 
fibrin network structure in AF may be helpful 
in predicting bleeding events during treatment 
with VKA and NOAC.
specific atrial fibrillation patient populations at risk 
of bleeding on anticoagulation Advanced age 
Older patients have a higher risk of bleeding; 
however, in the age group above 75 years, re­
duced ICB and increased GI bleeding on NOACs 
as compared with VKA share the same pattern 
as that observed in younger patients with AF.9 
In phase 3 AF trials, there were some differences 
in the bleeding risk in patients aged 75 years or 
older depending on the specific anticoagulants 
(FIguRE 2). Assessment of NOACs in elderly pa­
tients with AF showed increased rates of extra­
cranial major bleeding in those receiving both 
doses of dabigatran,50 and similar rates of bleed­
ing regardless of age were reported in RCTs with 
apixaban, edoxaban, or rivaroxaban.51-53 Com­
pared with warfarin, only apixaban was associ­
ated with a lower risk of major bleeding in pa­
tients above 75 years.53,54
Low body mass The risk of all ­cause death, stroke 
and SE, and major bleeding is higher in anticoag­
ulated patients with lower weight compared with 
those with normal weight.55 Low body weight 
may increase exposure to any NOAC and as such 
increases the risk of bleeding.56 Body weight of 
60 kg or less is a dose ­reduction criterion for apix­
aban.57 In the largest study evaluating NOACs in 
relation to body weight in patients with AF, apix­
aban was at least as efficacious as warfarin but 
safer across the range of weight, with the great­
est reduction in the risk of bleeding and hemor­
rhagic stroke in the group with body weight of 
60 kg or less.55 In patients with very low body 
weight (<50 kg), dabigatran’s efficacy and safe­
ty were similar to those observed in the remain­
der of the study cohort.58 However, observation­
al studies suggested that low body mass index 
(<23.9 kg/m2) may predict bleeding in patients on 
dabigatran.59 Of note, frequently coexisting renal 
insufficiency may make dabigatran a less prefera­
ble option for the underweight older patients with 
AF. Patients with low body weight on oral antico­
agulation should be monitored for bleeding risk.
Chronic kidney disease Patients with AF and 
chronic kidney disease (CKD) have an increased 
morbidity and mortality due to their excessive 
risk for both thromboembolic and severe bleed­
ing events, and risk stratification and treatment 
of patients with AF and CKD may be challenging.60 
All NOACs are eliminated by the kidneys, albeit 
to a different extent with the maximum value for 
dabigatran (80%), whereas 50%, 35%, and 27% of 
edoxaban, rivaroxaban, and apixaban, respective­
ly, are cleared via the kidneys in unchanged form. 
In all patients on NOACs, renal function needs to 
be monitored at least yearly. Importantly, inter­
current acute illness (eg, infections, acute heart 
they may improve discrimination of tradition­
al risk scores. In the ARISTOTLE (Apixaban for 
Reduction in Stroke and Other Thromboembol­
ic Events in Atrial Fibrillation) trial comparing 
apixaban with warfarin, blood biomarkers, name­
ly high ­sensitivity cardiac troponin T, growth dif­
ferentiation factor 15, and hemoglobin or  hema­
tocrit showed stronger association with bleed­
ing than most of clinical parameters.40 The ABC­
­bleeding score including those 3 biomarkers was 
validated in the population of the RE ­LY trial 
and performed better than the HAS ­BLED and 
ORBIT scores.41 However, these biomarkers are 
also nonspecifically associated with other cardio­
vascular outcomes (eg, stroke, death, heart fail­
ure)42 and some are not readily available in rou­
tine clinical practice.
Other biomarkers reflecting cardiovascu­
lar physiology, coagulation and fibrinolysis, are 
promising candidates for the development of new 
bleeding risk scores in AF.
We tested characteristics of plasma fibrin clot 
structure as potential new biomarkers which 
might help predict bleeding in patients with AF, 
given evidence indicating that fibrin clots com­
posed of thinner fibers, which are more compact 
and less permeable, are less susceptible to fibri­
nolysis.43 Recently, dense fibrin fiber networks, 
characterized by low plasma clot permeability, 
have been described as an independent predic­
tor of both thromboembolic events and major 
bleedings in patients with AF on VKA.44 We re­
ported that patients with lower clot permeabil­
ity had an increased risk of ischemic stroke or 
transient ischemic attack (TIA) (hazard ratio 
[HR], 6.55; 95% CI, 2.17–19.82) and major bleeds 
(HR, 10.65; 95% CI, 3.52–32.22), while patients 
with high permeability had elevated risk of mi­
nor bleeding compared with those with low fi­
brin clot permeability (11.63% per year vs 3.55% 
per year).45 Hypofibrinolysis, as reflected by pro­
longed clot lysis time, resulted in an 8 ­fold in­
crease in stroke or TIA rate in AF patients on 
a VKA (8.67% per year vs 1.1% per year).46 It was 
also observed that in patients with AF on riva­
roxaban, lower plasma clot permeability, deter­
mined as 24 to 30 hours since the intake of ri­
varoxaban, predicted ischemic cerebrovascular 
events (HR, 6.64; 95% CI, 2.2–20.1) and major 
bleedings (HR 7.38; 95% CI, 2.58–21.10), but 
not deaths, during follow ­up.47,48 Minor per­
sistent bleeding was associated with increased 
clot permeability in patients with AF on riva­
roxaban.47 Recently, an association between 
higher ORBIT bleeding risk score along with 
enhanced fibrinolysis and looser clot structure 
in AF has been reported.33 Despite still poorly 
understood mechanisms underlying the above 
observations, it might be speculated, based on 
experimental work, that denser clot meshwork 
within thrombi in vessels impair wound healing 
and adversely affect cell adhesion, migration, 
proliferation, which might enhance bleeding in 
particular from the GI tract.49 It remains to be 
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NOACs might be used with the dosing regimen 
adjusted to the estimated renal function, and con­
sideration of possible drug–drug interactions be­
tween NOACs and immunosuppressive agents.64
Liver disease Patients with active liver disease, 
including cirrhosis, or those with persistent (2 
measurments at least 7 days apart) elevation of 
the liver enzymes or bilirubin (eg, alanine trans­
aminase or aspartate transaminase ≥2–3 times 
the upper limit of normal or total bilirubin ≥1.5 
times the upper limit of normal) were excluded 
from the landmark NOAC trials in AF.13,14,18,58 
NOACs are contraindicated in patients with he­
patic disease associated with coagulopathy and 
clinically relevant bleeding risk including class 
C cirrhosis according to the Child–Pugh classi­
fication, while rivaroxaban should not be used 
even in patients with AF and Child–Pugh class 
B cirrhosis due to a more than a 2­fold increase 
in drug exposure in these individuals.65 Dabiga­
tran, apixaban, and edoxaban may be used with 
caution in patients with Child–Pugh class B cir­
rhosis. A reduced ­dose NOAC should be consid­
ered in patients with liver disease at high bleed­
ing risk, and close surveillance is advised in this 
subset. Lee et al,66 in a registry ­based study in pa­
tients with liver cirrhosis treated predominantly 
with low ­dose dabigatran and rivaroxaban, dem­
onstrated the risk of stroke / SE and ICB compa­
rable with warfarin and a reduced risk of major 
bleeding including GI bleeding. The advantage of 
NOACs over warfarin in the bleeding risk reduc­
tion was observed in the groups with nonalcohol­
ic and nonadvanced cirrhosis. In patients with ad­
vanced cirrhosis who presented with any compli­
cations such as ascites, encephalopathy, sponta­
neous bacterial peritonitis, or prior bleeding from 
esophageal varices, this benefit from NOACs was 
failure) may transiently affect renal function. Of 
note, renal function may be overestimated in un­
derweight patients due to their reduced muscle 
mass (especially when calculated with the Modi­
fication of Diet in Renal Disease formula). Com­
pared with warfarin, all 4 NOACs showed con­
sistent efficacy and safety in patients with mild 
to moderate CKD compared with non ­CKD pa­
tients in the respective subgroup analyses of piv­
otal NOAC trials.40,61-63 The ARISTOTLE trial data 
analysis suggests that the bleeding benefit with 
apixaban compared with warfarin becomes more 
prominent at lower creatinine clearance (CrCl) 
values, while the stroke reduction benefit is main­
tained.40,60 In contrast, the bleeding benefit of 
dabigatran at a dose of 110 mg twice a day over 
warfarin was not observed in patients with CrCl 
of less than 50 ml/min while a similar stroke risk 
reduction compared with VKA was maintained.62
All available trials on NOACs essentially exclud­
ed patients with a CrCl of less than 30 ml/min (ex­
cept for a few patients on apixaban with CrCl 25–
30 ml/min in the ARISTOTLE trial). Rivaroxaban, 
apixaban, and edoxaban (but not dabigatran) are 
approved in Europe for the use in patients with 
severe CKD (Stage 4, ie, a CrCl of 15–29 ml/min), 
with the reduced dose regimen. In Europe, NOACs 
should not be prescribed to patients with AF and 
severe renal dysfunction (CrCl <15 ml/min) as well 
as to patients on dialysis, whereas in the United 
States, apixaban was approved for hemodialyzed 
patients in 2014. Since VKA use leads to a high 
risk of bleeding in this subset of patients, the de­
cision to use a VKA in such patients is challenging 
and should be based on the individual patient’s 
risk of stroke, anticipated net benefit, and pa­
tient’s preferences.60
Regarding patients with AF after kidney trans­
plantation, high ­quality evidence is lacking, but 
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warfarin based on landmark randomized controlled trials 
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warfarin, the risk of GI bleeds is not increased 
for dabigatran 110 mg bid and apixaban 5 mg 
bid7 (FIguRE 3).
Co ­therapy with protein pump inhibitors is as­
sociated with 25% to 51% less hospitalizations 
due to GI bleeding during VKAs and NOACs use, 
with the most pronounced reduction observed for 
dabigatran, as the result of reduced direct muco­
sal toxicity of the drug and decreased dabigatran 
bioavailability71 (FIguRE 4). Approximately 1 in 12 
major bleedings in patients receiving warfarin or 
dabigatran is caused by an underlying cancer of 
the GI tract, most commonly colorectal cancer. 
Cancer ­related bleedings manifest sooner and are 
more frequently chronic than those of a nonma­
lignant or unidentified source. There was no dif­
ference observed in the short ­term outcome be­
tween dabigatran­ and warfarin ­related bleedings; 
however, the majority of patients required blood 
transfusions and prolonged hospital stay.71 Fur­
ther prospective studies are required to determine 
if GI cancer screening before and after initiation 
of anticoagulation, in particular the most com­
mon colorectal cancer, may allow earlier cancer de­
tection and treatment; however, baseline screen­
ing in high ­risk populations should be considered.
A history of a spontaneous ICB is a contrain­
dication for anticoagulation with VKAs and NO­
ACs based on the manufacturer’s recommenda­
tions, unless the cause of the bleeding (like un­
controlled hypertension, aneurysm or arterio­
venous malformation, or triple antithrombotic 
therapy) has been reversed.7,72 Reasons for not 
resuming or initiating anticoagulation in patients 
with ICB and AF should be assessed on an indi­
vidual basis.73 Patients with (probable) cerebral 
amyloid angiopathy have a very high risk of re­
current ICB and should not be anticoagulated.74 
Adequate blood pressure control is of paramount 
importance in all patients after ICB.73 Left atrial 
diminished, presumably due to reduced drug me­
tabolism and impaired hepatobiliary excretion.59
Of note, hepatotoxicity has been observed in 
less than 1% of patients with AF in the NOAC tri­
als at a similar rate to the warfarin arms.67 Usu­
ally, drug withdrawal normalized liver function 
markers within a few days. Search for underlying 
liver pathologies and hepatotoxic drugs, for ex­
ample, amiodarone, should be performed.
Prior serious bleeding In most bleedings due to 
secondary (eg, bleeding post ­trauma) or revers­
ible causes (eg, GI bleed due to colon polyps or 
peptic ulcer), anticoagulation can be resumed 
once the cause of the bleed is eliminated. Re­
­initiation of anticoagulation should be consid­
ered after 4 to 7 days after a GI bleed if bene­
fits outweigh potential risks of re ­bleeding.68,69 
Factors that need to be taken into consideration 
before preinitiation or withholding of antico­
agulation include identification of the bleed­
ing site, presence of reversible / treatable cause 
of bleeding and angiodysplasia in the GI tract, 
older age, chronic alcohol abuse, and need for 
antiplatelet therapy. Results from observation­
al studies on patients after GI bleeding suggest 
benefits from resuming anticoagulation without 
an increase in recurrent GI bleeding in the ma­
jority of patients with AF.70
In patients with AF at a high ­risk of GI bleed­
ing, the 2016 European Society of Cardiology 
guidelines recommend using VKAs or NOACs oth­
er than dabigatran at a dose of 150 mg bid, rivar­
oxaban, 20 mg once daily, and edoxaban, 60 mg 
once daily (class IIa, level of evidence B). The elim­
ination of modifiable bleeding risk factors, in par­
ticular alcohol abuse and cyklooxygenase ­1 inhib­
itors, is of key importance to minimize bleeding 
risk on anticoagulation. Importantly, the land­
mark AF RCTs indicate that, compared with 
FIguRE 3 Major gastrointestinal (GI) bleeding rates in patients with atrial fibrillation treated with non –vitamin K antagonist oral anticoagulants versus 
those on warfarin (based on Chai ‑Adisaksopha)12 
Abbreviations: GI, gastrointestinal; others, see FIguREs 1 and 2
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rates of stroke or TIA and death were observed 
in thrombocytopenic and normocytopenic pa­
tients. Of note, several cases of NOAC ­induced 
thrombocytopenia have been reported in the lit­
erature, which supports platelet count monitor­
ing during treatment.78
In patients with severe thrombocytopenia 
(<50 000/µl) and AF, the anticoagulation should 
be individualized and closely monitored given 
the lack of evidence from trials.
Cancer patients Atrial fibrillation is present in ap­
proximately 5% of patients with cancer at the time 
of diagnosis or within the first months of treat­
ment.79 Based on the current guidelines, about 
80% of patients with AF and cancer had indica­
tions for chronic anticoagulation.80 Of note, can­
cer is associated with an increased risk of bleed­
ing related to thrombocytopenia, metastases, kid­
ney and liver damage, vessel damage caused by 
a tumor infiltrating its wall, invasive procedures, 
and radiation therapy.69
Regarding patients with cancer and AF, most 
data are from observational studies.81 Random­
ized studies of patients with cancer and VTE, in­
cluding the Hokusai VTE Cancer trial with edox­
aban and SELECT ­D (Anticoagulation Thera­
py in Selected Cancer Patients at Risk of Recur­
rence of Venous Thromboembolism) trial with 
rivaroxaban, showed that NOACs use compared 
with dalteparin was associated with reduction in 
the recurrence rate of VTE and increased risk of 
major bleeding, mainly GI bleeding. The highest 
bleeding risk was observed in patients with esoph­
ageal, gastroesophageal, and urologic cancer.82,83
Shah et al,84 in a registry ­based study in a pop­
ulation of patients with AF and cancer, report­
ed lower or similar rates of bleeding and stroke, 
and a lower rate of VTE in NOAC users as com­
pared with VKA users. Although limited by 
the sample size, the lowest rates of VTE and se­
vere bleeding were observed for apixaban. Data 
appendage occlusion may be considered in some 
patients with AF after ICB as well as after recur­
rent intractable or untreatable major bleeding, al­
though evidence on the role of left atrial append­
age occlusion in such patients is lacking.7,75 How­
ever, antiplatelet treatment for at least 1 month 
post left atrial appendage occlusion is associat­
ed with increased bleeding risk in such patients, 
which should be taken into account especially in 
elderly patients with AF.
Thrombocytopenia It is estimated that up to 3% 
of patients with AF have thrombocytopenia, 
defined as a platelet count below 100 000/µl.76 
Although thrombocytopenia does not protect 
against thromboembolic events, patients with AF 
with platelet count below 90 000 to 100 000/µl 
were excluded from the landmark phase 3 NOAC 
trials.51-53
The current guidelines for the management of 
patients with AF do not provide any recommen­
dations for the use of NOACs in thrombocytope­
nic patients.68,69
In a retrospective study, the use of VKAs in pa­
tients with moderate thrombocytopenia of 50 000 
to 100 000/µl (mean platelet count, 87 900/µl) 
who had AF or VTE was associated with a 3 ­fold 
higher incidence of minor bleeding (5.55 vs 1.84 
per 100 patient ­years) and a tendency toward 
a higher risk of major bleeding. All the recorded 
bleeding complications occurred at INRs above 
2.5, which suggests using narrower INR targets 
and lower intensity oral anticoagulation.77 Sad­
owska et al76 demonstrated the acceptable safety 
and effectiveness of anticoagulation with NOAC 
at reduced doses in a cohort of patients with AF 
with moderate thrombocytopenia (mean plate­
let count, 78 000/µl). The risk of bleeding was 
unaffected by the type of NOAC (rivaroxaban, 
15 mg once daily; dabigatran, 110 mg bid; or apix­
aban, 2.5 mg bid), and was predicted only by age. 
Despite the dose reduction of a NOAC, similar 
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Andexanet alfa, which binds with high affin­
ity to direct factor Xa inhibitors and also low­
­molecular ­weight heparins and fondaparinux,93 
is a modified human recombinant factor Xa de­
coy protein that lacks catalytical activity follow­
ing replacement of an active ­site serine with ala­
nine and with removal of the membrane ­binding 
domain, which precludes this protein to partic­
ipate in the formation of the prothrombinase 
complex.15,92 Because of its pharmacodynamic 
half ­life of 1 hour, andexanet was administered 
as a bolus followed by an infusion, which leads 
to the normalization of anti–factor Xa activity 
within 2 hours.
The results of 2 RCTs (Andexanet Alfa, a Nov­
el Antidote to the Anticoagulation Effects of FXA 
Inhibitors trials [ANNEXA]) performed in healthy 
volunteers aged 50 to 75 years who received apix­
aban (ANNEXA ­A) and rivaroxaban (ANNEXA­
­R)93 demonstrated the efficacy and safety of an­
dexanet alfa. The phase 3b to 4 ANNEXA ­4 study 
confirmed the efficacy and safety of andexanet 
alfa in patients treated with factor Xa inhibitors 
with acute major bleeding.
In May 2018, andexanet alfa, which is a specif­
ic reversal agent for oral factor Xa inhibitors, was 
approved in the United States, and in 2019 in Eu­
rope, but currently it is unavailable in many coun­
tries. For this reason, the available Xa inhibitor re­
versal strategies rely on nonspecific strategies of 
unknown effectiveness, in particular prothrom­
bin complex concentrates (PCCs). Prothrombin 
complex concentrates are plasma ­derived prod­
ucts that contain 3 (factors II, IX, and X) or 4 (ad­
dition of factor VII) clotting factors in addition to 
variable amounts of heparin and natural coagu­
lation inhibitors, protein C and protein S, which 
are used among others to reverse anticoagulant 
effects of VKAs in patients with severe bleed­
ing. Activated PCC (also known as factor VIII in­
hibitor bypassing activity) contains mostly acti­
vated factor VII along with mainly nonactivated 
factors II, IX, and X. A dose of 50 U/kg of PCC or 
activated PCC is recommend in patients treated 
with rivaroxaban or apixaban if life ­threatening 
bleeding occurs.16,19
A prospective multicenter observational study 
showed that in the real world,94 reversal strat­
egies in bleeding patients on rivaroxaban or 
apixaban differ largely. A Swedish case series 
of 84 bleeding patients (75% with AF) who re­
quired reversal of factor Xa inhibition after 9 to 
16 hours since the last dose of the anticoagulant 
showed that in most cases (70% ICB and 16% GI 
bleeds), PCC at a dose of 2000 units was used 
in patients with body weight of 65 kg or more, 
while 1500 units were administered in patients 
weighted below 65 kg.95 No hemostatic effect of 
PCC was observed in 30.9% of patients, largely 
in those with ICB. Of note, 15 patients died, in­
cluding 13 patients following ICB (30 ­day mor­
tality rate, 32%), whereas 2 patients had fatal 
ischemic stroke at 5 and 15 days after the in­
dex bleeding.96
from registries suggested a higher number of 
hemorrhagic complications in patients with can­
cer and AF with concomitant metastatic disease, 
advanced CKD, recent bleeding (<30 days), and 
longer immobility.85
The 2019 ISTH guidelines regarding the use of 
NOACs in patients with AF and cancer receiving 
chemotherapy recommend individualized anti­
coagulation, based on the risk of stroke, bleed­
ing, and patient preferences. NOACs should be 
considered in patients with clinically relevant in­
teractions between VKAs and anticancer med­
ications that are not expected with NOACs, or 
in those unable to comply with INR monitoring. 
The use of NOACs over VKAs or heparins is sug­
gested in patients on chemotherapy with new­
ly diagnosed AF, with the exception of patients 
with luminal GI cancer and an intact primary 
tumor or active GI mucosal abnormalities.86 In 
a recent study in patients with colorectal cancer 
after surgery and first ­line chemotherapy treat­
ed with a NOAC, mainly rivaroxaban in a dose 
of 20 mg daily, the rate of TIA and stroke as well 
as major bleeding was relatively low, 4.0% and 
1.9%, respectively. A reduced dose of a NOAC 
was associated with higher risk of thromboem­
bolic events.87 Real ­world data on the effective­
ness and safety of NOACs in oncological patients 
suggest a clear benefit, especially in patients with 
favorable prognosis; however, the safety in spe­
cific subgroups of patients with cancer remains 
to be clarified.88,89
Reversal agents The use of specific and nonspe­
cific reversal agents in patients with AF on NOACs 
should be restricted to life ­threatening situations, 
predominantly ICB or posttraumatic bleeding.90
Idarucizumab is a humanized monoclonal an­
tibody fragment which is a specific reversal agent 
for dabigatran. It binds with 350 times higher 
affinity than thrombin to free and thrombin­
­bound dabigatran within minutes. This reac­
tion is irreversible.90
Idarucizumab was approved in Europe in No­
vember 2015. It has become the standard of care 
for the reversal of dabigatran when it is avail­
able. The RE ­VERSE AD (Reversal Effects of Ida­
rucizumab on Active Dabigatran) study assessed 
the safety and efficacy of 5 g idarucizumab (ad­
ministered as 2 rapid 2.5 g intravenous boluses) in 
dabigatran ­treated patients who presented with 
uncontrolled or life ­threatening bleeding (group 
A) or nonbleeding patients who required emer­
gent surgery or intervention (group B). The pri­
mary outcome of the RE­VERSE AD study was 
maximum percentage reversal of the anticoagu­
lant effect of dabigatran. The RE ­VERSE AD study, 
published as an interim analysis of the first 90 pa­
tients in 201591 and then a final analysis of 503 
patients in 2017,92 showed the utility of idaruci­
zumab in the 2 groups of patients. Now, idaru­
cizumab is the best therapeutic option for pa­
tients with AF on dabigatran who experience life­
­threatening bleeding.
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with patients receiving VKAs because NOAC plas­
ma levels do not require routine monitoring.
The 2018 European Heart Rhythm Associa­
tion guidelines on the use of NOACs in patients 
with AF recommend regular follow ­up assess­
ment during NOAC use, particularly in high ­risk 
groups with older age, renal failure, multiple co­
morbidities, and frailty.68 At each visit, the follow­
ing should be evaluated: adherence to treatment, 
comedications, presence of thromboembolic and 
bleeding complications as well as other side ef­
fects. Particular attention should be directed to 
minimizing modifiable bleeding risk factors and 
to assess an optimal NOAC and its correct dos­
ing. In patients on NOACs without renal impair­
ment, CrCl using the Cockcroft–Gault method 
should be monitored at least yearly. In case of 
kidney failure, a more frequent evaluation should 
be performed (recheck interval in months may be 
calculated from equation CrCl/10). Hemoglobin 
concentration and liver function should be mea­
sured at least once every 6 months in patients 
aged 75 years or older (especially if on dabiga­
tran) or with frailty, and yearly in other patients.
Limited data support the measurement of plas­
ma levels of NOACs in emergencies, before elec­
tive procedures, and during long ­term exposure. 
There are several special situations in which the 
assessment of drug exposure and anticoagulant 
effect may support clinical decisions. They include: 
1) thrombolytic therapy in stroke, 2) surgery or 
invasive procedure, 3) a need for immediate re­
versal of anticoagulation, 4) extreme body weight, 
5) substantial drug–drug interactions (eg, after 
transplantation, anti ­HIV treatment), 6) suspect­
ed noncompliance or overdosage in case of throm­
bosis or hemorrhage, respectively.97
Conclusions Overall, NOACs were comparable 
or superior to VKAs in most patients with AF 
as shown in RCTs and observational studies. In­
dividualization of anticoagulant therapy based 
on benefit and safety profiles as well as patient 
characteristics should be considered in particu­
lar in patients with AF at elevated risk of bleed­
ing, such as the elderly patients with several co­
morbidities and those with cancer (TAbLE 2). Giv­
en a high risk of stroke in most patients with AF 
as compared with bleeding risk, appropriate dos­
ing regimen should be used and reduced ­dose reg­
imen should be restricted to the recommended 
settings. Modifiable bleeding risk factors such 
as use of nonsteroidal anti ­inflammatory drugs 
available over the counter should be eliminated 
whenever feasible. 
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Analysis of 460 bleeds observed in patients 
on NOACs showed that almost 20% of those pa­
tients received vitamin K, which is useless in such 
clinical situations.94 It has absolutely no possibil­
ity of any effect, but was given probably because 
many of these patients had a prolonged INR due 
to rivaroxaban.97
Tranexamic acid, an antifibrinolytic agent ef­
fective in trauma or postpartum hemorrhages, 
acts as a lysine analog that impairs plasminogen 
activation on fibrin. In patients on NOACs, its 
efficacy is uncertain; however, it might be used.
Fresh frozen plasma is ineffective in patients 
bleeding on NOACs but was used in about 10% 
of patients reported by Xu Y et al.94 Fresh frozen 
plasma may be used as a plasma volume expand­
er in patients following transfusions; however, 
its shortcomings are numerous, including risk 
of transfusion reactions, and acute heart failure.
Experts strongly recommend that an institu­
tional policy concerning bleeding management is 
defined in every hospital. In patients on NOACs, 
the recommendations, including a protocol con­
taining the availability and indications of spe­
cific and nonspecific reversal agents, should be 
developed by cardiologists, hemostasis experts, 
intensivists and others, and this policy should 
be easily accessible for all physicians in a given 
institution.31,68
Patient preferences and knowledge in reducing bleed-
ing risk Optimal treatment strategies for stroke 
prevention incorporate patient preferences and 
values, which may differ from those of the physi­
cian. Results from a survey suggest that patients 
with AF who initiate oral anticoagulation are 
willing to sustain 4 major bleeds to avoid 1 se­
rious stroke.98 About half of the patients, main­
ly older, with minor or major bleeds on antico­
agulation and without history of cerebrovascu­
lar events, accept a low number of bleeds (0–
3). Our recent findings confirmed that patients 
with AF fear a major stroke more than bleeding, 
but they are less willing to accept such adverse 
events after a serious bleed in the past as well 
as in the presence of persistent minor bleed­
ing, for example, easy bruising.98 From a prac­
tical point of view, it is important to remem­
ber that only 1 out of 2 patients with AF treat­
ed with NOACs or VKAs is aware that the saf­
est painkiller is paracetamol, and 1 out of 4 pa­
tients knows what to do when an anticoagulant 
dose is missed. Among patients with AF, women, 
patients with diabetes, prosthetic heart valve, 
and minor bleedings were found to be better in­
formed about those issues.99 Better education 
about the disease and anticoagulation is likely 
to improve compliance and therapy outcomes in 
patients with AF,100 and activities aiming at im­
proving knowledge should be strongly support­
ed in everyday practice.
monitoring  Patients treated with NOACs are 
likely to be followed less frequently compared 
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